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Abstract
Background: Inappropriate antibiotic prescribing for nonbacterial infections leads to increases in the costs of care,
antibiotic resistance among bacteria, and adverse drug events. Acute respiratory infections (ARIs) are the most
common reason for inappropriate antibiotic use. Most prior efforts to decrease inappropriate antibiotic prescribing
for ARIs (e.g., educational or informational interventions) have relied on the implicit assumption that clinicians
inappropriately prescribe antibiotics because they are unaware of guideline recommendations for ARIs. If lack of
guideline awareness is not the reason for inappropriate prescribing, educational interventions may have limited impact
on prescribing rates. Instead, interventions that apply social psychological and behavioral economic principles may be
more effective in deterring inappropriate antibiotic prescribing for ARIs by well-informed clinicians.
Methods/design: The Application of Behavioral Economics to Improve the Treatment of Acute Respiratory Infections
(BEARI) Trial is a multisite, cluster-randomized controlled trial with practice as the unit of randomization. The primary
aim is to test the ability of three interventions based on behavioral economic principles to reduce the rate of
inappropriate antibiotic prescribing for ARIs. We randomized practices in a 2 × 2 × 2 factorial design to receive up to
three interventions for non-antibiotic-appropriate diagnoses: 1) Accountable Justifications: When prescribing an
antibiotic for an ARI, clinicians are prompted to record an explicit justification that appears in the patient electronic
health record; 2) Suggested Alternatives: Through computerized clinical decision support, clinicians prescribing an
antibiotic for an ARI receive a list of non-antibiotic treatment choices (including prescription options) prior to
completing the antibiotic prescription; and 3) Peer Comparison: Each provider’s rate of inappropriate antibiotic
prescribing relative to top-performing peers is reported back to the provider periodically by email. We enrolled 269
clinicians (practicing attending physicians or advanced practice nurses) in 49 participating clinic sites and collected
baseline data. The primary outcome is the antibiotic prescribing rate for office visits with non-antibiotic-appropriate ARI
diagnoses. Secondary outcomes will examine antibiotic prescribing more broadly. The 18-month intervention period
will be followed by a one year follow-up period to measure persistence of effects after interventions cease.
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Discussion: The ongoing BEARI Trial will evaluate the effectiveness of behavioral economic strategies in reducing
inappropriate prescribing of antibiotics.
Trials registration: ClinicalTrials.gov: NCT01454947
Keywords: Antibiotics, Acute respiratory infections, Behavioral economics, Social psychology, Clinical decision
support
Background
Acute respiratory infections (ARIs) constitute about 10%
of all ambulatory care visits in the United States and ac-
count for 44% all antibiotic prescriptions provided in
ambulatory care [1]. Despite the fact that the vast major-
ity of ARIs in adults are caused by viruses, antibiotic use
for ARIs remains common [1,2]. Although the Centers
for Disease Control and Prevention and others have
placed increased emphasis on reducing inappropriate
antibiotic use, prescribing rates declined only modestly be-
tween 1995 and 2006, and the use of broader-spectrum
antibiotics increased [1].
Clinicians who prescribe antibiotics for non-bacterial in-
fections expose patients to unnecessary risks of adverse
drug events, and increased costs [3]. Furthermore, anti-
biotic overuse increases the spread of antibiotic-resistant
bacteria which have become a major public health prob-
lem [2,4,5]. Interventions to reduce antimicrobial prescrib-
ing such as physician and patient education, physician
audit and feedback, and financial or regulatory incentives
have only been modestly successful, generally producing
10% reductions in antibiotic prescribing rates [6,7]. Educa-
tional interventions may have limited impact on prescri-
bing rates if lack of guideline awareness is not the primary
reason for inappropriate antibiotic prescribing.
Recognizing the limitations of educational and informa-
tional interventions, we developed novel interventions,
drawing on insights from behavioral economics and social
psychology, designed to appeal to provider self-image and
social motivation and thereby produce larger and more en-
during effects. These interventions take into account a
growing body of research indicating that individuals act
within broad social contexts and behave in ways that are
not always rational but may be predictable [8-11].
This article discusses the rationale, design, develop-
ment, and implementation of these interventions as part
of a cluster randomized controlled trial to evaluate the
use of behavioral economics in the treatment of ARIs.
Methods/design
Study aims
The main intent of this study is to determine whether
interventions that leverage information technology and
apply behavioral economic concepts reduce the rate of
antibiotic prescribing for ARIs. Our primary hypothesis
is that practices randomized to receive behavioral eco-
nomic interventions will have lower antibiotic prescrib-
ing rates for non-antibiotic appropriate ARIs compared
to control practices. We further hypothesize that for
the treatment conditions, individual prescribers’ rates of
antibiotic prescribing for encounters with a non-antibiotic
appropriate ARI diagnoses will decrease relative to their
own historical control rates.
Practice settings, physician recruitment and consent
We recruited physicians and advance practice nurses
from 49 primary care clinics affiliated with three health-
care organizations. Providers were eligible if they treated
adult patients with acute respiratory infections. Each
study clinic was required to have an electronic health
record (EHR) system in place and had to have its own
physical building (as opposed to multiple clinics sharing
the same space, such as the floor of a hospital, where in-
teractions between providers assigned to different inter-
vention groups would be more likely).
With the assistance of each site’s medical director, we
sent providers at participating sites an introductory
email that included a description of the broad goals of
the study, a general description of the intervention, and
a link to the electronic consent form and baseline sur-
vey. We also described compensation providers would
receive for participation. The leadership of each clinic
site decided whether the financial incentives to partici-
pate would be paid as a stipend to the clinic as a whole
or to the individual clinician. The amount of the com-
pensation provided to the clinic per participating pro-
vider was approximately the same regardless of whether
the clinic was randomized to no intervention, one inter-
vention, or multiple interventions ($1200 per full-time
provider). We sent up to 6 (median of 3) follow up emails
to providers who did not respond, and study personnel
contacted them in person when feasible.
Participating providers completed written informed
consent. The consent document indicated that participation
was voluntary and that decisions to participate (or not)
would have no bearing on any provider’s status at his or her
clinic. Providers who gave consent to participate were asked
to complete an online survey and brief educational session
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prior to the intervention phase, permit de-identified patient
records pertaining to patients who saw them for ARIs to be
included in the study database, and complete a 15 minute
post-intervention survey (See Additional file 1: Appendices
A and B).
The study protocol for all clinic sites was reviewed
and approved by the University of Southern California’s
Institutional Review Board (IRB). Individual protocols
for Massachusetts and California sites were reviewed
and approved by their local IRBs.
Provider education & baseline survey
After providing consent, all providers were asked to
complete a 15 to 20 minute online survey and educational
module. The educational module contained information
about ARIs derived from evidence based guidelines and
systematic reviews [12-21]. The educational module also
described the interventions to which a clinician’s site was
assigned, including changes they would observe in their
EHR (for Accountable Justifications and Suggested Alter-
natives interventions) and examples of the kinds of emails
they would receive (Peer Comparison). Additional file 1:
Appendix A provides examples of the content of these
enrollment and education materials.
Interventions
We developed intervention components (including cli-
nical decision support rules, planned workflows, and
computerized order sets) using current guidelines for
ARIs, as well as input from a research team comprised
of individuals with expertise in primary care, acute re-
spiratory infections, behavioral economics, clinical in-
formatics, and the capabilities of the existing EHR
systems used by each study site. The clinical decision
support was customized according to the capabilities of
the three EHR systems in use (NextGen, NextGen
Healthcare, Horsham, PA; EpicCare, Epic Systems Co.,
Verona, WI; and the Longitudinal Medical Record, Part-
ners Healthcare, Boston, MA). All interventions were
designed to minimize disruption in provider workflow
and to avoid limiting the treatment options available.
EHR-based interventions
The research team developed model workflows described
below for the two clinical decision support interventions
(Accountable Justifications and Suggested Alternatives).
These model workflows were iteratively modified to ac-
commodate technical constraints and organizational pre-
ferences for each of the three organizations. The Figure 1
illustrates the three workflows relevant to the design of
the study for each of the three EHRs used. Further accom-
modations were required to support the group rando-
mized in the factorial design to receive both interventions.
Additional file 1: Appendix C contains the details of
development and customization that was required at
each site.
Accountable justifications intervention
Rationale for accountable justifications
In the Accountable Justifications intervention, clinicians
are prompted to record an explicit justification for why
they are prescribing an antibiotic to a patient with an
ARI that appears in the patient’s EHR. Accountable justi-
fications incorporate several behavioral principles. First,
they signal an injunctive norm (a norm, often provided
by an authoritative source, that strongly indicates how
people should behave) indicating that prescribing an
antibiotic is not recommended. This may make the pro-
vider more likely to believe both that not prescribing an
antibiotic is the best medical decision and that prescribing
when it is not indicated violates professional standards.
Second, they incorporate social accountability. Provider
justifications become an explicit, separate part of the
medical record, so a provider’s decision to prescribe is
subject to the review and judgment of the provider’s
peers [22-24]. Third, the justification alert implicitly
designates guideline-concordant prescribing as the default
action. Defaults are options that are exercised if the deci-
sion maker takes no special action to opt in or out of a
given choice [25-28]. Prior to our intervention, choosing
to deviate from guidelines did not carry a special re-
quirement to document a clinical rationale in the EHR.
Accountable justifications, therefore, reset the default
action. Guideline-concordant treatment choices (i.e., not
prescribing an antibiotic for an ARI) continue to require
no special justification, but a provider must now “opt-in”
to prescribing an antibiotic by providing a justification for
which they are accountable.
Defaults may affect behavior for a number of reasons:
1) they may be perceived as a recommended action; 2)
they require less effort (in this case, by following the de-
fault a provider can avoid the workflow disruption caused
by the justification alert); 3) they serve as a reference point
so that relative disadvantages of alternatives are viewed as
losses that loom larger than relative advantages; and 4)
they may seem less anxiety-inducing as people tend to
regret active choices that lead to poor outcomes more
than they regret failures to act that lead to poor outcomes.
We expect all of these factors to contribute to a shift away
from inappropriate antibiotic prescribing [25,26].
Model workflow for delivery of accountable justifications
When a provider orders an antibiotic through the EHR
and enters a non-antibiotic appropriate ARI diagnosis
(listed in Table 1) a computerized alert appears (Additional
file 1: Appendix D). The alert briefly summarizes the
guideline corresponding to the ARI diagnosis for which
the antibiotic is being written (e.g., antibiotics are not
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indicated for non-specific upper respiratory infections). If
the provider persists in wanting to prescribe an antibiotic,
the alert asks the provider to check a box stating “If you
still want to prescribe an antibiotic, please check the box
and write your reason for doing so.” The clinician must
write his or her justification for prescribing the antibiotic
in a free-text field in the EHR; no pre-written justifications
are given. The alert informs the provider that the free-text
justification he or she provides will be inserted into the pa-
tient’s medical record where other providers can see it,
and that if he or she does not enter a justification, the
statement “No justification for prescribing antibiotics was
given” will be entered into the patients’ medical record. If
the antibiotic order is canceled no justification is required,
and this text will not appear.
These alerts are suppressed (i.e., do not appear) when a
patient has certain comorbid conditions recorded in the
EHR problem list or a past medical history (See Additional
file 2: Appendix E). These suppressor diagnoses were com-
piled by study physicians based on comorbid conditions
that may make the clinical guidelines on which the alerts
were based less likely to apply to an individual patient.
Suggested alternatives intervention
Rationale for suggested alternatives
When clinicians assigned to the Suggested Alternatives
intervention see a patient with an ARI, they receive a list
of non-antibiotic treatment choices prior to the time
when they would complete an antibiotic prescription.
Suggested Alternatives may be effective because one
central reason why physicians prescribe antibiotics for
ARIs when they are not indicated is perceived pressure
from patients requesting a prescription. Patients may be
unsatisfied if they do not receive an antibiotic prescrip-
tion, or at least a prescription for medication of some
kind [29]. By making prescription and over-the-counter
medications that are alternatives to antibiotics more sali-
ent to providers, we facilitate a means by which they can
satisfy patient demand for treatment from their provider
while at the same time reducing their tendency to pre-
scribe unnecessary antibiotics [26,30].
Model workflow for delivery of suggested alternatives
When a provider enters an ARI diagnosis for a patient visit,
a computerized alert presents an order set containing mul-
tiple non-antibiotic prescription and non-prescription medi-
cation choices as well as educational materials that can be
printed and given to the patient. These order sets were
designed to include many of the most common treatments
used to treat ARI symptoms. Additional file 1: Appendix F
provides sample content of an order set.
Peer comparison intervention
Rationale for peer comparisons
Social norms are standards that are understood by mem-
bers of a group and that guide relevant social behavior
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Figure 1 Work flow schema for the 3 electronic health records used.
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due to a desire to conform with actual behavior (the de-
scriptive norm) or sanctioned behavior (the injunctive
norm) [31]. Numerous studies have shown that people
tend to conform to the behavior of others, especially
those who are perceived to be similar to one’s self [32].
Such effects have been found in studies of behaviors as
diverse as voting, [33] littering, [31] and towel recycling
in hotels [34]. Social norms may convey information
concerning appropriate behavior or social consequences
of failing to conform. Behavioral studies find that
these effects persist even when behavior is unobservable
(e.g., littering when nobody is around) and when the
social information is not particularly informative to one’s
own preferences (e.g., towel recycling). We expect that
periodically reminding health care providers of their
own prescribing behavior, while providing both a de-
scriptive social norm (displaying the behavior of the best
performing peers in their region) and an injunctive norm
(citing the national recommended guidelines) will lead
providers to conform more closely to these norms.
While benchmarks and performance measurement
and public reporting have become increasingly common
in health care, [35,36] these reports typically include the
performance of all providers across the full range of per-
formance. However, providing individuals with statistics
of central tendency, such as the statistical mean, can
sometimes be ineffective or even backfire for individuals
who are currently performing better than the average
[37,38]. A seminal study by Kiefe et al. demonstrated
that providers who were shown their own performance
in relation to 90th percentile performance on measures
of preventive and chronic disease care had greater
performance improvements than those who were shown
their own performance in relation to mean performance
[37]. Thus, in the current study those in the Peer Com-
parison conditions are provided personalized feedback
along with the antibiotic over-prescribing rate of only
the top performers within their clinic. In addition, in-
junctive norms (i.e., indicators of socially desirable per-
formance for high performers) are often excluded. These
factors suggest that the use of benchmarks can be im-
proved by applying “nudging” interventions with founda-
tions in social decision making.
Our performance feedback reports for each provider
randomized to receive the Peer Comparison intervention
will have three key characteristics: (1) each target pro-
vider will receive his or her individual performance, (2)
benchmarks will prominently feature the performance of
providers who would be considered credibly peers of the
target provider, and (3) benchmarks will reflect only per-
formance that is desirable (e.g., showing only the per-
formance of the best-performing credible peers). Prior
studies of provider feedback related to antibiotic use for
ARIs have not constructed feedback in this way [39-42].
Delivery of peer comparisons
In the Peer Comparison intervention, each provider’s in-
dividual performance is calculated as the percentage of
encounters for non-antibiotic appropriate ARIs listed in
Table 1 for which the provider prescribed an oral anti-
biotic. Encounters occurring with patients who had cer-
tain comorbidities or other diagnosed bacterial infections
(Additional file 2: Appendix E) are excluded from the cal-
culation. If the provider had more than 20 qualifying ARI
Table 1 Acute Respiratory Infection (ARI) diagnoses related to interventions and outcomes assessments
Diagnoses ICD9-CM Used to trigger
decision support
Non-antibiotic appropriate ARI diagnoses (Included in Peer Comparison and Primary Outcome Assessment)
Acute nasopharyngitis (common cold) 460 Non-specific URI
Acute laryngitis and tracheitis 464, 464.0, 464.00, 464.1, 464.10, 464.2, 464.20, 464.4, 464.50 Non-specific URI
Acute laryngeopharyngitis/acute upper
respiratory infection
465, 465.0, 465.8, 465.9 Non-specific URI
Acute bronchitis 466, 466.0, 466.1, 466.11, 466.19 Acute bronchitis
Bronchitis not specified as acute or chronic 490 Acute bronchitis
Influenza 487, 487.1, 487.8 Influenza
Potentially antibiotic appropriate ARI Diagnoses (Included in Secondary Outcome Assessment)
Acute sinusitis 461.xx Acute sinusitis/rhinosinusitis
Acute pharyngitis 462 Acute pharyngitis
Other ARIs diagnoses or symptoms of interest (Included in Secondary Outcome Assessment)*
Streptococcal sore throat 034.0 Acute pharyngitis
Cough 786.2 Acute bronchitis
* Only additional diagnoses triggering clinical decision support are included here. Additional diagnoses included in the secondary outcomes are listed in
Additional file 2: Appendix E.
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encounters in the past 30 days, all these encounters were
included in the calculation. Otherwise, the most recent 20
qualifying ARI encounters were included if they occurred
in the past 5 months. If fewer than 20 occurred in the past
5 months, only encounters in the past 5 months are in-
cluded and the provider is excluded from percentile rank
calculations.
Providers randomized to Peer Comparison receive, via
email, feedback reports presenting their individual per-
formance, updated every 1–2 months. These emails clas-
sify their performance as “top performing” (among the
10% of their peers with the “best”—i.e. lowest— prescrib-
ing rates) or “not top performing” (for all providers not in
the best 10%). The top 10% of participating providers are
calculated within each study region: Massachusetts or
California. Emails to providers within the top 10% (lowest
prescribers) carry a brief message in the subject line: “You
are a top performer.” Emails to those not in the top 10%
have an equally direct subject line: “You are not a top per-
former. You are prescribing too many unnecessary antibi-
otics.” The proportion of “Top Performers” can be greater
than 10% of clinicians if more than10% of them had an in-
appropriate antibiotic prescribing rate of zero.
In addition to this overall classification of performance,
the feedback reports for each provider include a denomi-
nator count (the number of patient encounters for non-
antibiotic appropriate ARIs, after exclusions), a numerator
count (the number of denominator patient encounters in
which the provider prescribed an oral antibiotic), the pro-
vider’s own performance rate (the numerator divided by
the denominator), and the performance rate cutoff for the
best 10% of providers. Emails also include a link to the
guidelines for antibiotic usage in ARIs. Additional file 1:
Appendix G provides an example of emails sent to top
performers and non-top performers.
Randomization of study sites
We chose a cluster-randomized design at the clinic level
to avoid contamination that might occur if individual
providers in close proximity were randomized to differ-
ent interventions. Providers who practice at multiple
clinics were assigned to the intervention of the clinic for
which they spend at least 85% of their time. One pro-
vider who practiced at multiple clinics was assigned to
his own cluster.
Geographically distinct individual clinics were the unit
of randomization. Clinics belonged to one of three larger
clinical organizations covering a connected geographic
area in either Massachusetts (Partners Healthcare consist-
ing of Brigham and Women’s Hospital and Massachusetts
General Hospital affiliated primary care practices) or
Southern California (AltaMed; The Children’s Clinic—
which, despite its name, sees a high volume of adult pa-
tients). We carried out a block randomization of clinics by
clinic organization using the statistical computing lan-
guage R [43]. We first constructed two matrices that each
represented a main effects design and together repre-
sented the full factorial design (2 × 2 × 2 design). For each
clinic organization, we constructed ordered collections of
clinics. We then employed the sample function in R to re-
turn a random permutation of each ordered collection.
For each collection of clinic organizations we drew a sam-
ple that represented the largest number of clinics within
each clinic organization that was divisible by 8, the num-
ber of study arms. We then used the list function, a func-
tion that ties together related data that do not share the
same structure, to assign each randomly permutated clinic
to a study arm, repeating this process until clinics had
filled the eight arms of the study in equal measure. Be-
cause the number of clinics at each organization was not
always divisible by eight, there were a total of four “re-
mainder” clinics across all organizations. These remainder
clinics were randomized to four conditions within one of
the fractional factorial main effects design (a subset of the
larger 2 × 2 × 2 design) to maximize power for main ef-
fects estimates. This was accomplished in a procedure
similar to the one described above. One of the two pos-
sible fractional factorial designs of the larger 2 × 2 × 2 de-
sign was chosen randomly to assign remainder clinics to a
condition so that remainder clinics had an ex ante equal
probability of assignment to any one of the eight condi-
tions in the full factorial design. Allocation of the se-
quence was concealed until after the interventions were
assigned.
Intervention implementation
Dates for intervention implementation differ across geo-
graphical location, and were contingent upon variations
in organizational structure, provider recruitment proce-
dures, and EHR-specific development times for interven-
tion features. Interventions began at the first sites in
November 2011. The interventions will be in place for
18 months at each site. A one year follow up period after
the cessation of the interventions is planned to measure
persistence of the effects.
Measurements
We measured provider characteristics and attitudes by
survey. We also asked questions about providers’ atti-
tudes toward practice guidelines, clinical decision sup-
port, electronic health records, and practice environment.
Additional file 1: A provides the content of the provider
survey.
Outcomes
Primary outcome
The primary study outcome is whether a provider pre-
scribes an oral antibiotic (excluding antibiotics that are
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not used to treat any bacterial respiratory pathogens,
Additional file 1: Appendix H) during an eligible study
visit with a non-antibiotic appropriate ARI diagnosis
(listed in Table 1). At all study sites, providers prescribe
antibiotics through the EHR; handwritten prescriptions
are not used. An office visit is eligible for inclusion in
the outcome denominator if: 1) the patient was 18 years
old or older, 2) the provider and practice site were en-
rolled in the study, 3) the visit occurred during the 18-
month intervention period, and 4) the patient did not
have a visit with any ARI diagnosis in the prior 30 days.
Visits are excluded from the primary analysis when: 1)
patients have certain medical co-morbidities that make
ARI guidelines less likely to apply, 2) patients had con-
comitant visit diagnoses indicating a non-ARI possible
bacterial infection, or 3) patients had concomitant visit
diagnoses indicating potentially antibiotic appropriate
ARI diagnoses or other ARI diagnoses suggestive of a
bacterial infection. Visits for which a provider recorded
another condition that was not an ARI for which antibi-
otics might be indicated were also excluded from the
analysis. The sets of diagnoses used to calculate the out-
comes are listed in Additional file 1: Appendix E.
Secondary outcomes
We will examine oral antibiotic prescribing for the sub-
group of qualifying visits with diagnoses for potentially
antibiotic appropriate ARI diagnoses (acute sinusitis and
acute pharyngitis; Table 1); with the same additional in-
clusion and exclusion criteria above.
We will also examine the antibiotic prescribing rate for
all potential ARI visits in aggregate: non-antibiotic appro-
priate ARI diagnoses, potentially antibiotic appropriate
ARI diagnoses, and other ARI diagnoses of interest listed
in Table 1. Visits are excluded from this secondary analysis
when: 1) patients have medical co-morbidities listed in
Additional file 2: Appendix E, or 2) patients had concomi-
tant visit diagnoses indicating a non-ARI possible bacterial
infection (Additional file 1: Appendix E). Using a dif-
ferences-in-differences approach, we will determine
whether each intervention is associated with changes in the
proportion of all antibiotics prescribed for these diagnostic
categories, as compared to a pre-intervention period.
We will examine individual provider’s change in pre-
scribing for non-antibiotic appropriate ARI diagnoses,
potentially antibiotic appropriate ARI diagnoses, and
ARIs in aggregate. We will examine whether the effects
of the intervention differ according to the following pro-
vider subgroups: baseline prescribing rates (higher or
lower), provider gender, or health system affiliation.
Qualitative data
For clinicians randomized to the Accountable Justifica-
tion arm, we will use qualitative methods to analyze the
content of their written justifications for prescribing an-
tibiotics to patients with ARIs. To do this, we will create a
comprehensive codebook to classify each justification,
grouping the codes into coherent themes (e.g., guideline-
concordant, guideline-exception, guideline-nonconcordant).
Two or more trained physician coders will use the code-
book to classify each justification independently. After ini-
tial independent coding, all cases of disagreements
between coders will be resolved by discussion. Using the
final codings, we will examine the distribution of justifica-
tion codes in conjunction with clinicians’ antibiotic pre-
scribing rates and quantify the extent to which persistent
ARI antibiotic prescribing among Accountable Justifica-
tions clinicians is well-justified (i.e., prescribing that is ei-
ther concordant with guidelines or for patients who are
excluded from guidelines).
Statistical analysis plan
In our primary model, we will test the impact of each
of the 3 interventions and their interactions with each
other. That is we will estimate the random effects
model that an antibiotic will be prescribed at visit i by
provider j.
logit Pðyij ¼ 1j x
n o
¼ β0 þ β1xPC þ β2xAJ þ β3xSA þ β4xPCxAJ
þβ5xPCxSA þ β6xSAxAJ
þβ7xPCxSAxAJ þ εj
Where PC is Peer Comparison, AJ is Accountable
Justifications, and SA is Suggested Alternatives.
Safety assessment plan
A Data Safety and Monitoring Board has been estab-
lished. The board is composed of three physician experts
in acute respiratory infection care, and meets biannually
throughout the duration of the study to review patient
safety and adverse events. Following each meeting, the
board makes recommendations to the local IRBs as to
whether the study should continue or if changes to the
protocol are needed. Data for patients who have a return
visit to a study clinic within 30 days of an eligible study
visit with a diagnosis that could represent a serious com-
plication of an untreated bacterial infection (e.g. acute
rheumatic fever, head and neck abscess, intracranial ab-
scess, Lemierre syndrome, mastoiditis, meningitis, pneu-
monia, sepsis, etc.) will be extracted from study site
EHRs and reported to the Board.
Power calculation
Using the correction for inter-cluster correlation from
Kish, [44] we estimated the power of our study to detect
a clinically significant difference between binary condi-
tions. That is the sample size must be inflated by a factor
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of 1+ θ(m-1), where θ is the inter class correlation and
m is the number of ARI observations per cluster. In our
calculations we assumed an intra-clinic correlation of
0.055 6 and assumed a baseline antibiotic prescribing
rate of 50%, an ARI visit rate of 15 visits per month for
full time providers, and independence of treatments in
the factorials design. We calculated the number of visits
needed for an 80% chance to detect a clinically meaning-
ful difference in antibiotic prescribing (7%). We assumed
a 75% recruitment success rate for recruiting 376 eligible
providers across 49 sites, resulting in 141 providers per
study factor (282 providers total) and a one-sided α of
0.05. To achieve statistical power of 0.80 would require
a total of 2252 visits at each factor level, or 4504 visits
across all study conditions. Therefore, if each provider
had a minimum of 16 antibiotic-inappropriate ARI visits
over the course of the study, we would have sufficient
power to detect a clinically significant effect.
Results
Characteristics of participating providers and clinical sites
We enrolled 269 of the 376 providers offered enrollment
(72% participation rate). For Boston clinic participants,
the mean age of providers is 49 years, 60% are female, and
85% are physicians. For Los Angeles clinic providers, the
mean age is 45 years, are 61% female, and 71% are
physicians. These providers worked at 49 primary care
clinics affiliated with the 3 healthcare organizations
(22 clinics from the Boston region and 27 clinics from the
Los Angeles region). The results of the randomization
procedure and the numbers of eligible providers who en-
rolled in the study are depicted in Table 2.
Participating clinics represent diverse practice settings
and patient populations. The Los Angeles clinics are pre-
dominantly federally qualified community health centers or
other safety net clinics. The eastern Massachusetts clinics
are academically affiliated and have high proportions of pa-
tients with commercial or Medicare insurance. The patient
populations served by the eastern Massachusetts clinics are
predominantly white (approximately 75%), while the majo-
rity of patients served by the Los Angeles clinics is Hispanic
(84% at Alta Med and 71% at The Children’s Clinic),
with a high proportion of residents living at or below 200%
of the Federal Poverty Level.
Discussion
Using a multi-factorial design, three interventions will
be tested for their ability to alter inappropriate physician
prescribing behavior: 1) Accountable Justifications trig-
gered by guideline-discordant prescriptions that ask pro-
viders to provide their rationale for prescribing an
antibiotic and include these rationales in the medical
record; 2) Suggested Alternatives presented in EHR
order sets containing guideline concordant treatment
options for ARIs; and 3) Peer Comparisons communi-
cated through emailed performance feedback reports
that compare each provider’s own performance to his or
her top-performing peers. These interventions build on
two main preexisting quality improvement methods:
computerized clinical decision support and performance
Table 2 Results of clinic randomization and provider enrollment
Intervention Randomized
Clusters (n)
Providers enrolled (n) /
providers eligible (n)
Percentage of eligible
providers enrolled
Visits with non-antibiotic
appropriate ARI diagnoses
for enrolled providers in
prior year
No intervention 6 27 / 45 60% 1902
Accountable justifications 7 35 / 46 76% 1603
Suggested alternatives 6 44 / 57 77% 1658
Peer comparisons 6 33 / 37 89% 1141
Accountable justifications, suggested alternatives 6 36 / 49 73% 1592
Suggested alternatives, peer comparisons 6 36 / 58 62% 1861
Accountable justifications, peer comparisons 6 29 / 40 73% 1783
Accountable justifications, suggested alternatives,
peer comparisons
6 29 / 44 66% 2358
Any accountable justifications 25 129 / 179 72% 7336
No accountable justifications 24 140 / 197 71% 6562
Any suggested alternatives 25 145 / 208 70% 7469
No suggested alternatives 24 124 / 168 74% 6429
Any peer comparisons 24 127 / 179 71% 7143
No peer comparisons 25 142 / 197 72% 6755
ARI acute respiratory infection.
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feedback. The main innovation of the current study is
that the study interventions are specifically designed to
take advantage of irrational (but predictable) behavior
patterns common to most human beings—including
health care providers. In doing so, we hope to design in-
terventions that will lead to greater provider behavior
change than what has been observed in prior studies.
Anticipated challenges and limitations
This study is being conducted in diverse practices that
collectively use 3 different EHRs. This is both a limita-
tion and a strength. Due to their adaptation to each
EHR, the interventions differ somewhat across the dif-
ferent sites. The degree to which these differences might
influence the effectiveness of the interventions is un-
known, and we will examine whether the effects of each
intervention are modified by health system. Adapting
the study interventions to 3 different EHRs is a strength
in that the findings may be generalizable to a wider
range of practice settings than would findings from a
study conducted within one provider network using a
single information system.
Additional files
Additional file 1: List of Supplemental Materials. Appendix A: Survey
and sample educational module at start of study. Appendix B: Post-study
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decision support. Appendix F: Example of Suggested Alternatives order
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